arrow
G

Gwo Fuang Ho

Universiti Malaya
H指数:28
被引数:3,020

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study

度伐利尤单抗和特瑞普利单抗,联合或不联合伦伐替尼,与经动脉化疗栓塞联合用于栓塞适应证的肝细胞癌患者(EMERALD-3):一项全球、随机、开放标签、申办者设盲的III期研究

2026-08-240
PRE
Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1–high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part 1

度瓦尼单抗联合齐木利单抗作为PD-L1高表达、晚期非小细胞肺癌患者的一线治疗:来自随机II期ARC-10研究的结果,第一部分

2026-02-110
OAAI
Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation–positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study

达可替尼作为亚洲表皮生长因子受体(EGFR)突变阳性局部晚期或转移性非小细胞肺癌患者的一线疗法:ARIA研究的最终分析

2025-11-250
PRE
Pembrolizumab monotherapy for previously treated metastatic HER2-negative breast cancer with germline APOBEC3B deletion: results of the phase II AUROR study

帕博利珠单抗单药治疗既往接受过治疗的HER2阴性转移性乳腺癌(携带胚系APOBEC3B基因缺失):AUROR研究II期结果

2025-07-130
OA
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1

Cemiplimab单药治疗PD-L1表达≥50%的晚期NSCLC患者的一线治疗:EMPOWER-Lung 1研究五年结局

2025-03-190
OAAI
Dacomitinib with or without dose titration in treatment naive advanced EGFR mutated NSCLC: Primary analysis of the ATORG-003 phase II trial

达可替尼在治疗 naive 的晚期 EGFR 突变非小细胞肺癌中的剂量滴定或不滴定的比较:ATORG-003 II 期试验的主要分析

2024-12-010
PRE
Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial
2024-12-011
OAAI
Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase Ib/II study

Amivantamab联合FOLFOX或FOLFIRI治疗转移性结直肠癌:OrigAMI-1研究的结果,该研究是一项开放标签的Ib/II期研究

2024-09-010
PRE
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

Pembrolizumab单药治疗与化疗在铂类预处理,复发或转移性鼻咽癌中的比较 (KEYNOTE-122): 一项开放标签,随机,III期试验

2023-03-0138
OAAI
Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial
2022-11-010
OA